USARx offers the following ways to purchase this medication. Choose the Best option for you!
Pay this amount and pick up your prescription at ANY Retail pharmacy of your choice! Walgreens, CVS, Walmart, etc.
The easiest way to receive your medications.
Commonly reported side effects of selegiline include: application site reaction, dizziness, insomnia, and nausea. Other side effects include: abdominal pain, skin rash, weight loss, and orthostatic hypotension. See below for a comprehensive list of adverse effects.For the Consumer
Applies to selegiline: oral capsule, oral tablet, oral tablet disintegrating
Other dosage forms:
Along with its needed effects, selegiline may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking selegiline:
Incidence not known
Get emergency help immediately if any of the following symptoms of overdose occur while taking selegiline:
Symptoms of overdose
Some side effects of selegiline may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
For Healthcare Professionals
Applies to selegiline: compounding powder, oral capsule, oral tablet, oral tablet disintegrating, transdermal film extended releaseGeneral
In prospective pre-marketing studies, the most commonly reported side effects leading to treatment discontinuation with selegiline oral tablets were, in decreasing order of frequency, nausea, hallucinations, confusion, depression, loss of balance, insomnia, orthostatic hypotension, increased akinetic involuntary movements, agitation, arrhythmia, bradykinesia, chorea, delusions, hypertension, new or increased angina pectoris, and syncope.
In clinical trials with selegiline orally disintegrating tablets, the most commonly reported side effects leading to treatment discontinuation were dizziness, chest pain, accidental injury, and myasthenia. The relative risk for treatment-emergent hypertension and orthostatic or postural hypotension was reported as being at least 2 fold greater in patients 65 years or older compared to those younger than 65 years. Patients over 65 years were also reported at an increased risk for somnolence compared to younger patients.
In clinical trials with selegiline transdermal patches, application site reaction was reported as the side effect that lead to treatment discontinuation in at least 1% of patients at a rate at least twice that of placebo.
Selegiline potentiates the effects of levodopa; therefore, the side effects of levodopa may be emphasized unless the levodopa dose is reduced.Psychiatric
Very common (10% or more): Insomnia
Common (1% to 10%): Anxiety/tension, confusion, depression, euphoria, hallucinations, illusion, sleeping disorders, vivid dreams
Uncommon (0.1% to 1%): Abnormal dreams, agitation, manic reaction, mild transient irritability, mood change, psychoses
Frequency not reported: Apathy, delusions, disorientation, dreams/nightmares, hollow feeling, overstimulation, personality change, sleep disturbance, transient high, transient irritability
Postmarketing reports: Abnormal thinking, aggressive reaction, bruxism, delirium, impulse control disorders and compulsions, nervousness, paranoid reaction, paroniria, psychotic-like behavior
Insomnia and sleep disorder were reported as very common side effects with selegiline in double-blind placebo-controlled clinical trials at a higher frequency when used as adjunctive therapy with levodopa in the earlier phases of Parkinson's disease. Insomnia was also reported as a very common side effect in placebo-controlled clinical trials for major depressive disorder with transdermal selegiline.
Parkinson's disease patients treated with dopamine agonists and/or other dopaminergic treatments such as selegiline have been reported as exhibiting impulse control disorders such as pathological gambling, increased libido, hypersexuality, compulsive spending/buying, and binge eating. There have been very few cases reported with selegiline. In some cases, dose reduction or treatment discontinuation led to cessation of impulse control disorders.
Postmarketing reports have indicated that patients taking this drug may experience new or worsening mental status and behavioral changes, such as psychotic-like behavior, particularly after starting therapy or increasing the dose. Certain medications used to treat psychosis (e.g., dopamine antagonists) may exacerbate the symptoms of Parkinson's disease and may decrease the effectiveness of selegiline. Transient high and bruxism were reported at doses greater than 10 mg per day.
Anxiety was reported as a very common side effect with selegiline in double-blind placebo-controlled clinical trials when used as adjunctive therapy with levodopa in the earlier phases of Parkinson's disease.
Antidepressants may have a role in inducing worsening of depression and the emergence of suicidality in certain patients during the early phases of treatment. An increased risk of suicidal thinking and behavior in children, adolescents, and young adults (aged 18 to 24 years) with major depressive disorder (MDD) and other psychiatric disorders has been reported with short-term use of antidepressant drugs.
Adult and pediatric patients receiving antidepressants for MDD, as well as for psychiatric and nonpsychiatric indications, have reported symptoms that may be precursors to emerging suicidality, including anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, hypomania, and mania. Causality has not been established.Nervous system
Very common (10% or more): Dizziness/lightheadedness/fainting
Common (1% to 10%): Abnormal movements (e.g., dyskinesias, bradykinesia, akinesia), ataxia, headache, impaired balance, lethargy, somnolence, syncope, tremor
Frequency not reported: Chorea, drowsiness, dyskinesia, dystonic symptoms, facial grimace, festination, impaired memory, increased apraxia, involuntary movements, migraine, myoclonic jerks, numbness of toes/fingers, restlessness, speech affected, supraorbital pain, tardive dyskinesia
Postmarketing reports: Abnormal gait, cerebrovascular disorder, coma, convulsions, hypertonia, involuntary muscle contractions, neuroleptic malignant syndrome, serotonin syndrome, taste disturbance
There have been reports of falling asleep while engaged in activities of daily living, including the operation of motor vehicles, which sometimes resulted in accidents, in Parkinson's disease patients treated with this drug. These reports have occurred in a setting of pre-existing somnolence.
Impaired memory and myoclonic jerks were reported at doses greater than 10 mg per day. Seizure in dialyzed chronic renal failure in a patient treated with selegiline on concomitant medications has been reported in postmarketing experience.
A symptom complex resembling the neuroleptic malignant syndrome, with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in, antiparkinson therapy.
There have been postmarketing reports of fatal and non-fatal cases of serotonin syndrome with concomitant use of this drug with antidepressants.
Headache was reported as a very common side effect in placebo-controlled clinical trials for major depressive disorder with transdermal selegiline.Cardiovascular
Very common (10% or more): Postural hypotension
Common (1% to 10%): Arrhythmia, bradycardia, chest pain, hypertension, hypotension, edema, palpitations
Uncommon (0.1% to 1%): Angina pectoris, ankle edema, orthostatic hypotension, supraventricular tachycardia
Frequency not reported: Peripheral edema, hematoma, tachycardia
Postmarketing reports: Flushing, myocardial infarction
This drug inhibits the catabolism of dietary amines such as tyramine, and has the potential to produce a hypertensive crisis following the ingestion of tyramine-rich foods or beverages.
Postural hypotension was reported with selegiline in double-blind placebo-controlled clinical trials at a higher frequency when used as adjunctive therapy with levodopa in the earlier phases of Parkinson's disease compared to the late phase. Palpitation was also reported as a very common side effect in the earlier phases of Parkinson's disease in these trials.Gastrointestinal
Very common (10% or more): Dry mouth, irritation of the buccal mucosa (orally disintegrating tablet), mouth ulceration, nausea, stomatitis
Common (1% to 10%): Abdominal pain, constipation, diarrhea, dyspepsia, dysphagia, eructation, flatulence, gastric irritation, tooth disorder, vomiting
Frequency not reported: Gastrointestinal bleeding (exacerbation of pre-existing ulcer disease), heartburn, rectal bleeding, throat burning
Constipation was reported as a very common side effect with selegiline in double-blind placebo-controlled clinical trials when used as adjunctive therapy with levodopa in the earlier phases of Parkinson's disease.Other
Increased energy was reported at doses greater than 10 mg per day.
Vertigo was a very common side effect reported with selegiline in double-blind placebo-controlled clinical trials when used as adjunctive therapy with levodopa compared with its use as monotherapy.
Very common (10% or more): Fatigue
Common (1% to 10%): Fall, pain, vertigo
Frequency not reported: Chills, generalized ache, falling down, freezing, heavy leg, increased energy, malaise, tinnitus, tiredness, weakness
Postmarketing reports: Asthenia, death, feverDermatologic
Very common (10% or more): Rash
Common (1% to 10%): Ecchymosis, increased sweating, skin disorders
Uncommon (0.1% to 1%): Hair loss, skin eruptions
Frequency not reported: Facial hair, photosensitivity
Skin disorders reported with this drug have included skin ulcer, fungal dermatitis, skin hypertrophy, contact dermatitis, herpes simplex, dry skin, sweating, urticaria, and pruritus.Genitourinary
Very common (10% or more): Micturition disorder
Common (1% to 10%): Urinary retention
Frequency not reported: Hypersexuality, nocturia, penile sensation, prostatic hypertrophy, sexual dysfunction, slow urination, transient anorgasmia, urinary frequency, urinary hesitancy
Postmarketing reports: Increased libido
Transient anorgasmia and decreased penile sensation were reported at doses greater than 10 mg per day. The estimates of the incidence of untoward sexual experience and performance may also underestimate their actual incidence, partly because patients and physicians may be reluctant to discuss this issue.Hematologic
Uncommon (0.1% to 1%): Leucocytopenia, thrombocytopeniaHepatic
Common (1% to 10%): ALT/AST increased
Uncommon (0.1% to 1%): Transient increase in liver enzyme valuesLocal
Very common (10% or more): Application site reactions (transdermal patch)
Application site reactions with the transdermal patch were primarily described as erythema and resolved spontaneously with no treatment.Metabolic
Very common (10% or more): Anorexia
Common (1% to 10%): Hypokalemia, weight loss
Uncommon (0.1% to 1%): Loss of appetite
Postmarketing reports: Hyperglycemia, hypoglycemia
The 1.25 mg orally disintegrating tablet contains 1.25 mg phenylalanine.
Anorexia was reported as a very common side effect with selegiline in double-blind placebo-controlled clinical trials when used as adjunctive therapy with levodopa in the earlier phases of Parkinson's disease.Musculoskeletal
Common (1% to 10%): Arthralgia, back pain, leg cramps, leg pain, low back pain, myalgia, musculoskeletal injuries, muscle cramps
Uncommon (0.1% to 1%): Myopathy
Frequency not reported: Muscle twitch, stiff neck
Postmarketing reports: Muscle weakness (myasthenia)
Muscle twitch was reported at doses greater than 10 mg per day.Ocular
Common (1% to 10%): Abnormal accommodation
Uncommon (0.1% to 1%): Blurred vision
Frequency not reported: Blepharospasm, diplopia
Postmarketing reports: Abnormal visionOncologic
Epidemiological studies have shown that Parkinson's disease patients are at a 2- to 6-fold increased risk of developing melanoma than the general population. It is unclear whether the observed increase in risk is due to Parkinson's disease or other factors.
Frequency not reported: MelanomaRenal
Frequency not reported: Small increments in serum BUN and creatinine
Small increments in serum BUN and creatinine were observed with high doses of orally disintegrating selegiline (10 mg orally per day).Respiratory
Common (1% to 10%): Dyspnea, hiccup, nasal congestion, pharyngitis, rhinitis, sinusitis, sore throat
Frequency not reported: Asthma
October 19, 2020
October 19, 2020
October 19, 2020
October 19, 2020
October 19, 2020
October 13, 2020